SIA
AZN icon

Stancorp Investment Advisers’s AstraZeneca AZN Stock Holding History

Stancorp Investment Advisers’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$349K Buy
5,096
+995
+24% +$69.1K 0.16% 136
2014
Q4 		$289K Buy
+4,101
New +$294K 0.13% 144

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
MAA
Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
SCCM
Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Stancorp Investment Advisers's AZN Position: Q1 2015 in Review

Stancorp Investment Advisers increased its AstraZeneca (AZN) stake by 24% in Q1 2015, buying an estimated $69.1K and bringing the position to 5,096 shares worth $349K. The position accounts for 0.16% of the portfolio, ranked #136.

Stancorp Investment Advisers first reported a position in AZN in Q4 2014 and has held it in 2 quarters since. 385 funds tracked by Wall St. Rank hold AZN as of Q1 2015.

  • Stancorp Investment Advisers held 5,096 shares of AstraZeneca worth $349K as of Q1 2015.
  • Stancorp Investment Advisers bought 995 AstraZeneca shares in Q1 2015, an estimated $69.1K.
  • AstraZeneca made up 0.16% of Stancorp Investment Advisers's portfolio in Q1 2015, its #136 holding.
  • Stancorp Investment Advisers first reported a position in AstraZeneca in Q4 2014 and has held it in 2 quarters since.
  • 385 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2015.

Based on Stancorp Investment Advisers's 13F filing for Q1 2015, filed 13 May 2015.